Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence

Sunnybrook Health Sciences Centre1 site in 1 country125 target enrollmentSeptember 2009

ConditionsStress Urinary Incontinence

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Stress Urinary Incontinence
Sponsor: Sunnybrook Health Sciences Centre
Enrollment: 125
Locations: 1
Primary Endpoint: The primary endpoints are the cure/improvement rate in the cohort at 12 months.
Status: Terminated
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective, non-randomized, observational, multicentre (5 sites) study in which subjects that have surgically-correctable Stress Urinary Incontinence undergo a TVT SECUR operative procedure.

The study will collect preoperative urologic testing, medical history, and subject quality of life patient questionnaires, Intraoperative procedural data will be collected.

Postoperative complications, urologic, testing, and subject questionnaires will be collected at intervals up to 24 months. The anatomic position of the device will be characterize by transvaginal ultrasound testing.

To determine the rate and/or improvement rate of patients who have received the Gynecare Secur device after 12 months and after 24 months.

Registry

clinicaltrials.gov

Start Date

September 2009

End Date

September 2012

Last Updated

14 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Sunnybrook Health Sciences Centre

Eligibility Criteria

Inclusion Criteria

•To be considered eligible to participate in this study, subjects must meet the following requirements:
•Subject has agreed to undergo surgical implantation of the TVT SECUR System
•Subject has the complaint of SUI for at least 6 months prior to the Preoperative Evaluation Visit.
•Subject has confirmed SUI resulting from urethral hypermobility on cough stress testing.
•Subject has at least 4 gm of urine leakage on 1-hour pad testing during the Preoperative Screening Visit.
•Subject is at least 18 years of age to maximum of 85 years of age
•Subject is willing and able to give written informed consent prior to any study related procedures.
•Subject is willing to return for follow-up evaluation and questionnaire completion at 4-6 weeks, and at 3, 6, 12 and 24 month follow-ups.
•Subject is willing to undergo transvaginal ultrasound evaluation at the 4 weeks and 12 month follow-up visit.

Exclusion Criteria

•Subjects will not be eligible for entry into the study if they meet one of the following criteria:
•Subject is pregnant.
•Subject has had any previous synthetic sub-urethral sling procedure.
•Subject has current urinary tract or vaginal infections.
•Subject has blood coagulation disorders.
•Subject has a compromised immune system or any other conditions that would compromise healing.
•Subject has upper urinary tract obstruction.
•Subject is unwilling to provide written informed consent.
•Subject is unwilling or unable to return for evaluation at 4-6 weeks, and at 3, 6, 12, and 24 months.
•Subject has uncontrolled detrusor overactivity.

Outcomes

Primary Outcomes

The primary endpoints are the cure/improvement rate in the cohort at 12 months.

Time Frame: 12 months

Secondary Outcomes

Distribution of percentage of subjects having a decrease of pad weight as compared to baseline(24 months)
Decrease in number of pads used within a 24-hour period as compared to baseline(24 months)
Change in patient questionnaires from baseline(24 months)
Change in the sling position on transvaginal ultrasound(24 months)
Cure/improvement rate at 24 months(24 months)